Adding an Antianginal to a Resting Heart Rate of 58
Guidelines treat beta-blockers and calcium channel blockers as interchangeable first steps for stable angina. His resting heart rate of 58, documented and asymptomatic, makes them clearly not interchangeable for him.
D.V., a 67-year-old man, spent over three decades as a cattle auctioneer before retiring, and has taken up woodworking this past year, building furniture in the barn that used to hold his equipment. He has known two-vessel coronary artery disease, stented in the left anterior descending four years ago, and has been stable on aspirin, a statin, and an ACE inhibitor since — no beta-blocker was ever added, since he had no reduced ejection fraction or prior MI indication for one at the time. He has mild osteoarthritis in both knees, managed with occasional acetaminophen, otherwise unremarkable for a man his age.
He now describes exertional chest tightness climbing the stairs to his shop loft, reproducible, relieved by rest — new angina symptoms in a patient whose disease had otherwise been quiet for four years. His resting heart rate on today's visit is 58, sinus rhythm, asymptomatic, and consistent with prior visits going back at least two years, including two separate annual physicals where nobody flagged it as a problem; it appears to be his real baseline rather than an acute finding or a medication effect, since he has never been on a rate-limiting agent. Guideline language treats beta-blockers and calcium channel blockers as largely interchangeable first-line antianginal add-ons, but that equivalence assumes a patient starting from an ordinary resting rate. A documented, longstanding rate of 58 changes what either drug class actually does to him: a further rate-lowering agent doesn't just treat his angina, it also narrows the room between his baseline and clinically significant bradycardia, in a way the guideline's general equivalence doesn't account for.
At the new-symptom visit
His resting rate of 58 is real and longstanding, not an artifact of today's visit, and it changes which first-line agent makes sense. A dihydropyridine like amlodipine gives him coronary and peripheral vasodilation without touching heart rate at all, which respects the room he doesn't have to spare.
I'd push back gently. Beta-blockade has the strongest anti-ischemic mechanism of anything we'd reach for here — reducing rate-pressure product directly addresses demand ischemia in a way a dihydropyridine's afterload reduction only does indirectly. And the routine post-PCI beta-blocker halo, even without a reduced-EF or prior-MI indication, is something a lot of cardiologists still lean on.
I'd want to be honest that the evidence for that halo specifically in patients without MI or reduced EF is weaker than the reflex suggests — it's more inherited practice than a clean mortality signal at this point.
I don't think this needs to be decided on the strength of the post-PCI halo, since that argument is admittedly softer than it used to be. What's concrete is a measured, repeated resting rate of 58 with no compelling separate indication for beta-blockade — no MI, preserved EF. Amlodipine addresses his new angina without touching a parameter he has little room in. If it doesn't control his symptoms adequately, a cautious low-dose beta-blocker with close monitoring is still available, but it shouldn't be the first move here.
Amlodipine 5 mg daily started; existing aspirin, statin, and ACE inhibitor unchanged. Reassessment of angina symptoms in 4 weeks.
Not agreed, and left explicitly open rather than resolved by consensus:
No beta-blocker needed; the disagreement about the post-PCI halo remains academic for his case specifically.
A cautious low-dose beta-blocker gets added with closer rate monitoring, and the two physicians' disagreement about how much weight the halo deserves becomes practically relevant.